bellerophon
provides
clinical
program
update
reports
third
quarter
financial
results
warren
globe
newswire
bellerophon
therapeutics
nasdaq
blph
bellerophon
company
biotherapeutics
company
focused
developing
treatments
cardiopulmonary
infectious
diseases
today
provided
clinical
program
update
reported
financial
results
third
quarter
ended
september
bellerophon
continues
advance
multiple
development
programs
inhaled
nitric
oxide
therapy
said
fabian
tenenbaum
chief
executive
officer
bellerophon
pleased
rate
enrollment
ongoing
covinox
phase
clinical
trial
inopulse
treatment
results
planned
interim
analysis
expected
shortly
first
patients
completed
assessment
period
support
development
manufacturing
plans
applied
government
funding
discussions
number
federal
agencies
including
operation
warp
pivotal
phase
rebuild
trial
fibrotic
interstitial
lung
disease
fild
patients
risk
associated
pulmonary
hypertension
initiated
first
clinical
research
sites
allowing
us
begin
patient
enrollment
continued
tenenbaum
phase
trial
builds
upon
successful
phase
studies
look
forward
presenting
phase
results
design
phase
rebuild
trial
week
american
thoracic
society
ats
interstitial
lung
disease
mini
symposia
pulmonary
fibrosis
foundation
pff
moreover
continue
operate
position
financial
strength
importantly
current
balance
sheet
provides
us
resources
progress
inopulse
development
program
upcoming
catalysts
results
phase
rebuild
trial
concluded
tenenbaum
clinical
program
highlights
coronavirus
covinox
phase
study
bellerophon
continues
enroll
patients
company
ongoing
phase
clinical
study
inopulse
inhaled
nitric
oxide
ino
therapy
treatment
anticipates
availability
results
planned
interim
analysis
shortly
phase
randomized
covinox
study
evaluating
efficacy
safety
investigational
inopulse
therapy
patients
diagnosed
require
supplemental
oxygen
covinox
protocol
utilizes
adaptive
design
aims
enroll
patients
treated
either
inopulse
placebo
major
hospitals
primary
endpoint
assess
proportion
subjects
respiratory
failure
mortality
allow
trial
serve
registrational
study
approval
parallel
bellerophon
applied
government
funding
remains
ongoing
discussions
multiple
federal
agencies
support
company
development
manufacturing
plans
fild
rebuild
phase
study
bellerophon
successfully
completed
meetings
food
drug
administration
finalized
phase
rebuild
registrational
study
inopulse
treatment
fild
first
research
sites
phase
rebuild
study
initiated
allowing
company
begin
recruiting
patients
trial
rebuild
study
enroll
fild
patients
treated
either
inopulse
placebo
primary
endpoint
change
moderate
vigorous
physical
activity
mvpa
approved
inopulse
would
become
first
therapy
treat
broad
fild
population
includes
patients
pulmonary
hypertension
bellerophon
reported
positive
results
phase
randomized
clinical
study
inopulse
treatment
fild
subjects
treated
higher
dose
chronically
four
months
demonstrated
clinically
statistically
significant
improvement
mvpa
minutes
per
day
representing
improvement
improvements
mvpa
supported
benefits
activity
parameters
well
two
patient
reported
questionnaires
university
california
san
diego
shortness
breath
questionnaire
george
respiratory
questionnaire
results
cohort
study
published
august
edition
chest
journal
results
established
safety
dose
confirmed
potential
inopulse
provide
clinically
meaningful
benefits
levels
daily
activity
patient
population
results
cohort
study
presented
ats
interstitial
lung
disease
mini
symposia
results
demonstrated
safety
efficacy
dose
established
dose
endpoints
pivotal
rebuild
phase
study
addition
bellerophon
present
planned
phase
rebuild
study
upcoming
pff
meeting
pulmonary
phase
clinical
study
bellerophon
continuing
enrollment
phase
dose
escalation
study
anticipates
availability
data
around
end
safety
efficacy
study
assessing
acute
hemodynamic
benefit
inopulse
via
right
heart
catheterization
unmet
medical
need
median
survival
approximately
five
years
diagnosis
similar
treated
currently
available
systemic
vasodilators
corporate
update
august
bellerophon
strengthened
management
team
appointment
cardiopulmonary
disease
expert
wassim
fares
mscr
chief
medical
officer
september
company
presented
cantor
fitzgerald
virtual
global
healthcare
conference
wainwright
annual
global
investment
conference
third
quarter
ended
september
financial
results
three
months
ended
september
company
reported
operating
loss
million
compared
million
three
months
ended
september
three
months
ended
september
company
reported
net
loss
million
per
basic
diluted
share
compared
net
loss
million
per
basic
diluted
share
three
months
ended
september
research
development
expenses
three
months
ended
september
million
compared
million
prior
year
period
increase
primarily
due
increased
activities
related
development
inopulse
treatment
fild
patients
general
administrative
expenses
three
months
ended
september
million
compared
million
prior
year
period
increase
primarily
due
higher
expenses
related
financing
ip
legal
fees
nine
months
ended
september
financial
results
nine
months
ended
september
company
reported
operating
loss
million
compared
million
nine
months
ended
september
nine
months
ended
september
company
reported
net
loss
million
per
basic
diluted
share
compared
net
loss
million
per
basic
diluted
share
nine
months
ended
september
net
loss
nine
months
ended
september
included
expense
million
due
change
fair
value
company
common
stock
warrant
liability
compared
income
million
nine
months
ended
september
research
development
expenses
nine
months
ended
september
million
compared
million
prior
year
period
increase
primarily
due
increased
activities
related
development
inopulse
treatment
fild
patients
general
administrative
expenses
nine
months
ended
september
million
compared
million
prior
year
period
increase
primarily
due
higher
expenses
related
financing
ip
legal
fees
balance
sheet
september
company
cash
cash
equivalents
million
compared
million
december
bellerophon
bellerophon
therapeutics
biotherapeutics
company
focused
developing
innovative
therapies
address
significant
unmet
medical
needs
treatment
cardiopulmonary
infectious
diseases
company
currently
developing
multiple
product
candidates
program
proprietary
pulsatile
nitric
oxide
delivery
system
information
please
visit
statements
statements
press
release
bellerophon
future
expectations
plans
prospects
including
statements
clinical
development
product
candidates
regulatory
actions
respect
company
clinical
trials
expectations
regarding
sufficiency
company
cash
balance
fund
clinical
trials
operating
expenses
capital
expenditures
statements
containing
words
anticipate
believe
continue
contemplate
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
constitute
statements
within
meaning
private
securities
litigation
reform
act
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
uncertainties
inherent
initiation
future
clinical
trials
availability
timing
data
ongoing
future
clinical
trials
results
trials
whether
preliminary
interim
results
clinical
trial
predictive
final
results
trial
whether
results
early
clinical
trials
indicative
results
later
clinical
trials
expectations
regulatory
approvals
fda
substantial
discretion
approval
process
availability
funding
sufficient
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
factors
discussed
risk
factors
section
company
recent
annual
report
form
subsequent
filings
securities
exchange
commission
addition
statements
included
press
release
represent
bellerophon
views
date
release
relied
upon
representing
company
views
subsequent
date
company
specifically
disclaims
obligation
update
statements
included
press
release
contacts
group
lifesci
advisors
julie
normart
brian
ritchie
jnormart
britchie
bellerophon
therapeutics
condensed
consolidated
balance
sheets
thousands
except
share
per
share
data
september
december
unaudited
assets
current
assets
cash
cash
equivalents
restricted
cash
prepaid
expenses
current
assets
total
current
assets
restricted
cash
right
use
assets
net
property
equipment
net
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
research
development
accrued
expenses
current
portion
operating
lease
liabilities
total
current
liabilities
long
term
operating
lease
liabilities
common
stock
warrant
liability
total
liabilities
commitments
contingencies
stockholders
equity
common
stock
par
value
per
share
shares
authorized
shares
issued
outstanding
september
december
respectively
preferred
stock
par
value
per
share
shares
authorized
zero
shares
issued
outstanding
september
december
additional
capital
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
bellerophon
therapeutics
condensed
consolidated
statements
operations
unaudited
thousands
except
share
per
share
data
